New drug cocktail aims to beat back lymphoma in relapsed patients

NCT ID NCT06563596

First seen Feb 24, 2026 · Last updated May 13, 2026 · Updated 6 times

Summary

This study tests a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo works at shrinking tumors and to check for side effects. About 45 adults who have had at least one prior therapy will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10021, United States

    Contact Email: •••••@•••••

    Contact

  • The Ohio State University Wexner Medical Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.